SAN DIEGO--(EON: Enhanced Online News)--Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced that there will be
two poster presentations on tesetaxel at the 2018 American Society of
Clinical Oncology (ASCO) Annual Meeting to be held June 1 – 5, 2018 in
Chicago, Illinois. Abstracts for these presentations were made publicly
available today and can be found on the ASCO website at http://abstracts.asco.org
and by clicking the titles below.

Tesetaxel is an investigational, orally administered chemotherapy agent
that belongs to a class of drugs known as taxanes, which are widely used
in the treatment of cancer. Tesetaxel has several potential therapeutic
advantages over currently available taxanes, including: oral
administration with a low pill burden and a patient-friendly dosing
regimen; no history of hypersensitivity (allergic) reactions; and robust
activity against chemotherapy-resistant tumors. More than 500 patients
have been treated with tesetaxel across 22 clinical studies. In patients
with locally advanced or metastatic breast cancer (MBC), tesetaxel was
shown to have robust single-agent antitumor activity in two,
multicenter, Phase 2 studies.

About CONTESSA

CONTESSA is a multinational, multicenter, randomized, Phase 3 study of
tesetaxel, an investigational, orally administered taxane, in patients
with locally advanced or metastatic breast cancer (MBC). CONTESSA will
compare tesetaxel dosed orally at 27 mg/m2 on the first day
of a 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m2/day
dosed orally on days 1-14 of a 21-day cycle) to the approved dose of
capecitabine alone (2,500 mg/m2/day dosed orally on days 1-14
of a 21-day cycle) in approximately 600 patients randomized 1:1 with
human epidermal growth factor receptor 2 (HER2) negative, hormone
receptor (HR) positive MBC previously treated with a taxane in the
neoadjuvant or adjuvant setting. Capecitabine is an oral chemotherapy
agent that is considered a standard-of-care treatment in MBC. Where
indicated, patients must have received endocrine therapy with or without
a cyclin-dependent kinase (CDK) 4/6 inhibitor. The primary endpoint is
progression-free survival (PFS) assessed by an Independent Radiologic
Review Committee (IRC). CONTESSA’s secondary efficacy endpoints are
overall survival, objective response rate (ORR) assessed by IRC, disease
control rate assessed by IRC and patient-reported outcomes. To learn
more, please visit www.contessastudy.com.

About Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the
development of best-in-class therapeutics that improve and extend the
lives of patients with cancer. Odonate’s initial focus is on the
development of tesetaxel, an investigational, orally administered
chemotherapy agent belonging to a class of drugs known as taxanes, which
are widely used in the treatment of cancer. Odonate recently initiated
CONTESSA, a multinational, multicenter, randomized, Phase 3 study of
tesetaxel in patients with locally advanced or metastatic breast cancer
(MBC). Odonate’s goal for tesetaxel is to develop an effective
chemotherapy choice for patients that provides quality-of-life
advantages over current alternatives. To learn more, please visit www.odonate.com.

Forward-looking Statements

This press release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. We caution
investors that forward-looking statements are based on management’s
expectations and assumptions as of the date of this press release and
involve substantial risks and uncertainties that could cause the actual
outcomes to differ materially from what we currently expect. These risks
and uncertainties include, but are not limited to, those associated
with: the outcome of CONTESSA, our Phase 3 study of tesetaxel in
patients with locally advanced or metastatic breast cancer; our ability
to obtain regulatory approval of tesetaxel; and other risks and
uncertainties identified in our filings with the United States
Securities and Exchange Commission. Forward-looking statements in this
press release apply only as of the date made, and we undertake no
obligation to update or revise any forward-looking statements to reflect
subsequent events or circumstances.

Recent Stories

SAN DIEGO--(EON: Enhanced Online News)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the liv... more »

SAN DIEGO--(EON: Enhanced Online News)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the liv... more »

SAN DIEGO--(EON: Enhanced Online News)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the liv... more »